- Home
- BON vs KZIA Comparison
BON vs KZIA Comparison
Compare BON & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BON
- KZIA
- Stock Information
- Founded
- BON 2006
- KZIA 1994
- Country
- BON China
- KZIA Australia
- Employees
- BON N/A
- KZIA N/A
- Industry
- BON Medicinal Chemicals and Botanical Products
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- BON Health Care
- KZIA Health Care
- Exchange
- BON Nasdaq
- KZIA Nasdaq
- Market Cap
- BON 929.6K
- KZIA 860.8K
- IPO Year
- BON 2021
- KZIA 1999
- Fundamental
- Price
- BON $0.06
- KZIA $3.64
- Analyst Decision
- BON
- KZIA Strong Buy
- Analyst Count
- BON 0
- KZIA 2
- Target Price
- BON N/A
- KZIA $57.50
- AVG Volume (30 Days)
- BON 57.2M
- KZIA 30.1K
- Earning Date
- BON 05-02-2025
- KZIA 05-02-2025
- Dividend Yield
- BON N/A
- KZIA N/A
- EPS Growth
- BON N/A
- KZIA N/A
- EPS
- BON 0.17
- KZIA N/A
- Revenue
- BON $23,844,556.00
- KZIA $1,655,324.00
- Revenue This Year
- BON $223.38
- KZIA N/A
- Revenue Next Year
- BON $18.82
- KZIA N/A
- P/E Ratio
- BON $0.35
- KZIA N/A
- Revenue Growth
- BON N/A
- KZIA 248000.00
- 52 Week Low
- BON $0.05
- KZIA $2.86
- 52 Week High
- BON $5.31
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- BON 31.48
- KZIA 44.45
- Support Level
- BON $0.05
- KZIA $2.86
- Resistance Level
- BON $0.07
- KZIA $3.77
- Average True Range (ATR)
- BON 0.02
- KZIA 0.50
- MACD
- BON 0.04
- KZIA 0.05
- Stochastic Oscillator
- BON 10.00
- KZIA 60.00
About BON Bon Natural Life Limited
Bon Natural Life Ltd is engaged in the manufacturing of personal care ingredients, such as plants extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. Xi'an App-Chem is devoted to providing high quality and competitive prices and a stable supply of products and services for the functional food, personal care, natural medicine and other industries. It provides these products and services for third party customers, as well as for its own proprietary brands. The company has its geographic presence in PRC and in Overseas. The company derives maximum revenue from Bioactive food ingredients.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.